ITRM

Company Overview — What Does Iterum Therapeutics plc Do?

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc (ITRM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Corey N. Fishman and employs approximately 10 people. With a market capitalization of $2M, ITRM is one of the notable companies in the Healthcare sector.

Iterum Therapeutics plc (ITRM) Stock Rating — Avoid (April 2026)

As of April 2026, Iterum Therapeutics plc receives a Avoid rating with a composite score of 18.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ITRM ranks #4,423 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Iterum Therapeutics plc ranks #834 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ITRM Stock Price and 52-Week Range

Iterum Therapeutics plc (ITRM) currently trades at $0.18. The stock gained $0.00 (2.2%) in the most recent trading session. The 52-week high for ITRM is $1.50, which means the stock is currently trading -88.3% from its annual peak. The 52-week low is $0.14, putting the stock 29.1% above its annual trough. Recent trading volume was 670K shares, suggesting relatively thin trading activity.

Is ITRM Overvalued or Undervalued? — Valuation Analysis

Iterum Therapeutics plc (ITRM) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 4.10x, compared to 1.66x for the average Healthcare stock.

At current multiples, Iterum Therapeutics plc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Iterum Therapeutics plc Profitability — ROE, Margins, and Quality Score

Iterum Therapeutics plc (ITRM) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 285.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -81.5% versus the sector average of -33.1%.

On a margin basis, Iterum Therapeutics plc reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1982.3% (sector: -66.1%). Net profit margin stands at -2302.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ITRM Debt, Balance Sheet, and Financial Health

Iterum Therapeutics plc has a debt-to-equity ratio of -170.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.13x, indicating strong short-term liquidity. Total debt on the balance sheet is $20M. Cash and equivalents stand at $11M.

ITRM has a beta of 0.96, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Iterum Therapeutics plc is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Iterum Therapeutics plc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Iterum Therapeutics plc reported revenue of $390,000 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-26M. Gross margin was 100.0%. Operating income came in at $-22M.

In Q3 2025, Iterum Therapeutics plc reported revenue of $390,000 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-9M. Operating income came in at $-8M.

In Q2 2025, Iterum Therapeutics plc reported revenue of $0 and earnings per share (EPS) of $-0.16. Net income for the quarter was $-7M. Operating income came in at $-6M.

In Q1 2025, Iterum Therapeutics plc reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-5M. Operating income came in at $-4M.

Over the past 8 quarters, Iterum Therapeutics plc has demonstrated a growth trajectory, with revenue expanding from $0 to $390,000. Investors analyzing ITRM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ITRM Dividend Yield and Income Analysis

Iterum Therapeutics plc (ITRM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ITRM Momentum and Technical Analysis Profile

Iterum Therapeutics plc (ITRM) has a momentum factor score of 7/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

ITRM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Iterum Therapeutics plc (ITRM) ranks #834 out of 838 stocks based on the Blank Capital composite score. This places ITRM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ITRM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ITRM vs S&P 500 (SPY) comparison to assess how Iterum Therapeutics plc stacks up against the broader market across all factor dimensions.

ITRM Next Earnings Date

No upcoming earnings date has been announced for Iterum Therapeutics plc (ITRM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ITRM? — Investment Thesis Summary

The quantitative profile for Iterum Therapeutics plc suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 7/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, Iterum Therapeutics plc (ITRM) earns a Avoid rating with a composite score of 18.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ITRM stock.

Related Resources for ITRM Investors

Explore more research and tools: ITRM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ITRM head-to-head with peers: ITRM vs AZN, ITRM vs SLGL, ITRM vs VMD.